ODTX — Odyssey Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1882782 ·
Last close
$18.61
Market Cap
$893.86M
52W High
$20.30
52W Low
$15.10
ADV30
373,515
Next earnings
2026-08-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -39,671,000 | -38,262,000 | 229,070,000 | 35,719,000 | 752,764,000 |
| Mar 2025 | 1,918,000 | — | -44,808,000 | -38,435,000 | — | — | — |
| Dec 2024 | 1,755,000 | — | -37,121,000 | -35,932,000 | 197,435,000 | 59,136,000 | 579,962,000 |
| Sep 2024 | — | — | — | — | 221,535,000 | 39,435,000 | 570,801,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-113,944,000
Investing CF
$116,069,000
Financing CF
$7,503,000
CapEx
$-1,340,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.21
As of
2026-06-21
Balance + Analyst (yfinance extras)
Retained Earnings
$-606,401,000
Inventory
—
Receivables
—
ST Investments
$140,030,000
EBIT TTM
$-112,363,000
Pretax Income TTM
$-112,379,000
Interest Exp TTM
$16,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,058,000
EBITDA
$-145,796,000
Free Cash Flow
$-85,049,128
Enterprise Value
$1,444,945,792
Total Cash
$175,748,992
Total Debt
$26,127,000
Shares Out
48,031,320
Trailing EPS
$-3.22
Book Value
$-211.05
ROE
-85.5%
ROA
-41.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,976,000 | -161,156,000 | -148,647,000 | 269,788,000 | 758,066,000 | — | -129,468,000 |
| Dec 2024 | 4,472,000 | -135,223,000 | -129,321,000 | 197,435,000 | 579,962,000 | — | -117,471,000 |
| Dec 2023 | 1,037,000 | -133,439,000 | -125,938,000 | 286,521,000 | 549,229,000 | — | -112,728,000 |
| Dec 2022 | 0 | -122,776,000 | -124,665,000 | 317,150,000 | 461,770,000 | — | -99,842,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REPL | Replimune Group, Inc. | $902.41M | $10.75 | — |
| SANA | Sana Biotechnology, Inc. | $868.27M | $3.12 | — |
| DBVT | DBV Technologies S.A. | $806.66M | $13.63 | — |
| SLDB | Solid Biosciences Inc. | $797.44M | $8.10 | — |
| VOR | Vor Biopharma Inc. | $1.06B | $19.51 | — |
News headlines (Yahoo Finance, 1h cache)
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-06-17 20:15 · Yahoo
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
2026-05-11 12:31 · Yahoo
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
2026-05-08 00:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.